Emcitate (tiratricol)

MCT8 deficiency

Manufacturer: Egetis Therapeutics
Regulatory submission: NDA submitted January 2026 and approved September 2026
Launch: Anticipated eight to ten weeks after the September 2026 approval
Last updated: September 29, 2026

Section

Product information and disease description Product description

Product information

93 evidence topics · 25 sources

Generic, brand name and therapeutic class of product5 evidence topics · 7 sources
Dosage forms and strengths6 evidence topics · 4 sources
Average sales price and wholesale acquisition cost3 evidence topics · 2 sources
American hospital formulary service (AHFS), or other drug classification1 evidence topic · 1 source
Indication2 evidence topics · 2 sources
Pharmacology17 evidence topics · 13 sources
Contraindications/Warnings/Precautions/Adverse effects11 evidence topics · 5 sources
Special populations6 evidence topics · 2 sources
Drug/Drug, drug/disease interactions12 evidence topics · 3 sources
Dosing and administration17 evidence topics · 6 sources
Access and distribution9 evidence topics · 4 sources
Co-prescribed/Concomitant therapies2 evidence topics · 3 sources
Product comparison2 evidence topics · 3 sources

Effect of tiratricol on quality measures

No evidence found.